Liver scans, biopsies, and function studies were reviewed in 63 cancer patients and correlated with autopsy material to determine the value of the liver scan in such patients. The scan is abnormal in 96% of patients with autopsy-confirmed hepatic disease, but the scan pattern is of little assistance in differentiating tumor from nontumor pathology. Liver function studies are equally nonspecific and even less sensitive than the scan. Percutaneous biopsy, while diagnostic when positive, is insensitive, showing false-negative results in up to 40% of cases. The liver scan, as the most sensitive indicator of liver disease, may be most valuable when normal, reflecting a better prognosis and aiding in the determination of treatment. When the liver scan is abnormal, more specific tests must be employed. A method of approach is suggested. Whang et al., 1965). It is difficult t o compare these studies for several reasons: the use of different radiopharmaceuticals, improvements in techniques and in the experience of the nuclear medicine physician, the failure in older studies t o obtain The mentioning of trade names or manufacturers does not constitute approval of or endorsement by the U.S. Government.